NeoGraph Analytics
PharmaceuticalsEast Asia2023 – 2032

Asia Pacific RNA Therapeutics Market Size, Share, Growth and Forecast to 2032

Asia Pacific RNA Therapeutics market valued at USD 1.2B in 2023, projected to reach USD 4.1B by 2032 at a 14.5% CAGR.

Revenue, 2023

$1.2B

Forecast, 2032

$4.1B

CAGR, 2024-2032

14.5%

Report Coverage

East Asia

Code: asia-pacific-rna-therapeutics-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

The Asia Pacific RNA Therapeutics market was valued at USD 1.2 billion in 2023 and is projected to reach USD 4.1 billion by 2032, growing at a CAGR of 14.5%. Driven by mRNA vaccine success, expanding oncology pipelines, and increasing government investment in China, Japan, and India, the region is emerging as a high-growth hub. Key players include Moderna, BioNTech, and Alnylam, with local partnerships accelerating adoption.

02

Key Highlights

1

Asia Pacific RNA Therapeutics market projected to reach USD 4.1 billion by 2032 at 14.5% CAGR.

2

mRNA therapeutics dominate the market driven by COVID-19 vaccine success and expanding oncology pipeline.

3

China, Japan, and India are the fastest-growing markets with increasing government biotech investment.

4

RNAi and ASO therapies gaining traction for rare diseases, cardiovascular conditions, and oncology applications.

03

Market Overview

Market Context

RNA therapeutics leverage ribonucleic acid mechanisms to treat diseases at the genetic level. The Asia Pacific region, led by China, Japan, and India, is witnessing rapid adoption driven by pandemic preparedness, rising chronic disease burden, and expanding biotech infrastructure. mRNA vaccines dominate current revenue while RNAi and ASO therapies gain traction.

The Asia Pacific RNA Therapeutics market reached USD 1.2 billion in 2023 and is forecasted to grow to USD 4.1 billion by 2032 at a 14.5% CAGR. mRNA therapeutics lead the segment, with RNAi and ASO therapies rapidly expanding.

Market Stage

High growth

Adoption Level

Growing

Key Trends

mRNA vaccine platform expansion beyond COVID-19 into oncology and infectious diseasesIncreasing government biotech funding in China, Japan, South Korea, and IndiaGrowing local manufacturing capabilities reducing import dependencyRising clinical trials for siRNA and ASO therapies targeting rare diseases
04

Market Forecast & Data

Market Growth Forecast
2024-2032 · CAGR 14.5%

Base Year (2023)

$1.2B

Forecast (2032)

$4.1B

CAGR (2024-2032)

14.5%

Market size by year, 2024-2032, in USD Billion.
YearMarket size ($ Billion)
2023Base year$1.20B
2024$1.37B
2025$1.57B
2026$1.80B
2027$2.06B
2028$2.36B
2029$2.70B
2030$3.10B
2031$3.55B
2032$4.06B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Forecast Analysis

The Asia Pacific RNA Therapeutics market is poised for robust growth, expanding from USD 1.2B in 2023 to USD 4.1B by 2032. mRNA therapeutics will dominate, while siRNA and ASO segments gain share. China and Japan lead adoption, with India emerging as a high-growth market.

Regional Market Analysis
Market share and growth rate by region
Regional market analysis — market share, growth rate and largest market by region.
RegionMarket shareGrowth rateLargest market
East Asia45.0%15.8%China
South Asia25.0%16.2%India
Southeast Asia18.0%13.5%Japan
Oceania12.0%12.0%Australia

East Asia

#1
Share: 45.0%CAGR: 15.8%

Largest market: China

South Asia

#2
Share: 25.0%CAGR: 16.2%

Largest market: India

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
05

Market Dynamics

  • Successful mRNA COVID-19 vaccines validating platform for diverse therapeutic applications
  • Rising government funding and biotech infrastructure in China, Japan, and India
  • Expanding oncology and rare disease pipelines using RNA-based modalities
06

Market Segmentation

By Application
Market share distribution across 5 segments
By Application — market share by segment, in percent.
SegmentShare
OncologyLargest application segment driven by mRNA cancer vaccines and siRNA-based tumor suppression therapies.35.0%
Infectious DiseasesSecond-largest segment primarily from mRNA vaccines for COVID-19, influenza, and RSV.25.0%
Rare DiseasesGrowing segment with ASO and siRNA therapies targeting genetic disorders across the region.20.0%
CardiovascularEmerging segment with RNA-based therapies for hypercholesterolemia and heart failure.10.0%
Other Therapeutic AreasIncludes metabolic disorders, neurological diseases, and autoimmune conditions.10.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
By Therapy Type
Market share distribution across 4 segments
By Therapy Type — market share by segment, in percent.
SegmentShare
mRNA TherapeuticsDominant segment driven by vaccine success and expanding oncology and infectious disease pipelines.45.0%
siRNA TherapeuticsGrowing rapidly with RNAi platforms targeting rare diseases and cardiometabolic disorders.25.0%
ASO TherapeuticsEstablished segment with approved therapies for Duchenne muscular dystrophy and spinal muscular atrophy.20.0%
Other RNA TherapeuticsIncludes aptamers, miRNA, and emerging RNA modalities in early-stage development.10.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.

By End User

  • Hospitals
  • Specialty Clinics
  • Research Institutes
07

Regional Analysis

1

East Asia

Lead: China
CAGR: 15.8%Share: 45.0%

Largest APAC sub-region driven by strong government biotech policies, local mRNA manufacturing, and large patient populations.

2

South Asia

Lead: India
CAGR: 16.2%Share: 25.0%

Fastest-growing sub-region with cost-effective generics manufacturing and rising chronic disease burden.

3

Southeast Asia

Lead: Japan
CAGR: 13.5%Share: 18.0%

Mature market with advanced healthcare infrastructure and strong regulatory frameworks supporting RNA therapeutic adoption.

4

Oceania

Lead: Australia
CAGR: 12.0%Share: 12.0%

Stable market with growing clinical trial activity and partnerships with global RNA therapeutic developers.

Country-Level Analysis

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Market share and growth rate by country
CountryShareGrowth
China
35.0%
+16.5%
Japan
25.0%
+13.0%
India
20.0%
+18.0%
08

Competitive Landscape

M

Moderna, Inc.

USA

Leader18.5B

Dominant mRNA platform with diversified pipeline including oncology and respiratory therapeutics across APAC partnerships.

Global mRNA therapeutics leader with diversified pipeline including respiratory vaccines, oncology (mRNA-4157/V940 with Merck), and rare disease programs across Asia Pacific partnerships.

B

BioNTech SE

Germany

Challenger22.0B

Strong mRNA vaccine developer expanding oncology therapeutics and manufacturing partnerships in China and Southeast Asia.

Pioneering mRNA oncology and vaccine developer expanding manufacturing and clinical partnerships across China, Japan, and Southeast Asia.

A

Alnylam Pharmaceuticals, Inc.

USA

Follower2.3B

RNAi therapeutics pioneer with patisiran and vutrisiran leading siRNA pipeline expansion into APAC markets.

Leading RNAi therapeutics company with FDA-approved siRNA treatments expanding into APAC markets through partnerships and regional licensing agreements.

09

Recent Developments

25
2025Moderna

Established mRNA manufacturing facility in Japan to support Asia Pacific vaccine and therapeutic supply.

25
2025BioNTech

Signed strategic partnership with Chinese biotech firms to co-develop mRNA oncology therapeutics for Greater China market.

24
2024Alnylam

Received regulatory approval in Japan for Amvuttra (vutrisiran) expansion to treat polyneuropathy from hereditary ATTR amyloidosis.

24
2024CureVac

Launched Phase III clinical trials for next-generation mRNA COVID-19 vaccine candidate in collaboration with Indian pharmaceutical partners.

10

Regulatory Landscape

Japan PMDA has established expedited approval pathways for regenerative and advanced therapeutic RNA medicinesChina NMPA introduced conditional approval mechanisms for innovative biologics including mRNA and RNAi therapeuticsIndia CDSCO is aligning ICH guidelines to streamline RNA therapeutic clinical trial approvalsAustralia TGA participates in joint reviews with PMDA and FDA under international recognition agreements
11

Research Methodology

Primary research

  • Expert interviews with APAC biotech executives
  • Surveys of pharmaceutical companies and research institutes
  • Interviews with regulatory consultants

Secondary research

  • Industry association reports
  • Company financial filings and annual reports
  • Published clinical trial databases
  • Government healthcare expenditure data

Validation: Triangulation method combining top-down market sizing with bottom-up company revenue analysis and expert validation

12

Strategic Takeaways

Investors

The 14.5% CAGR presents strong long-term growth potential, particularly in mRNA oncology and siRNA rare disease segments across China and India.

Operators

Local manufacturing partnerships and regulatory navigation are critical competitive advantages in the fragmented APAC landscape.

Policymakers

Harmonizing regulatory frameworks across APAC jurisdictions could accelerate market access and attract global RNA therapeutic developers.

Healthcare Providers

Early adoption of approved RNA therapeutics in oncology and rare diseases will position institutions as regional treatment centers.

13

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.